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After over more than six decades of broad-based multilateral trade 
liberalization under the General Agreement on Tariffs and Trade (GATT), and 
subsequently the World Trade Organization (WTO), trade in agricultural products is 
still constrained by high barriers to market access for imports. These barriers consist 
of both traditional tariffs and a plethora of non-tariff barriers. Until the Uruguay 
Round (1986-1994) of GATT negotiations, trade in agricultural products was largely 
exempt from multilateral disciplines pertaining to market access due to waivers 
granted in the early years of the GATT. While the conclusion of the Uruguay Round 
brought the rules of trade for agricultural products within the general WTO 
framework, tariff concessions were few, and in the end significant improvements in 
market access were largely thwarted by dirty tarifficaction and the continued 
widespread use of non-tariff barriers. Many members of the WTO continue to show 
little enthusiasm for the liberalization of market access for agricultural products. 
As a result of the continued reticence of some countries to liberalize their 
agricultural markets, no agreement has been reached in the Doha Round negotiations 
that began in 2001 – market access for agricultural products remains a major 
stumbling block to completion of the round (Gifford et al., 2008). Even if the Doha 
Round were to succeed, what has arisen thus far in the negotiations shows only 
limited ambition. It seems that the traditional approach to liberalizing market access 2 
 
may not be able to deliver much progress, and those interested in securing better 
access should explore alternative means to accomplish their goals. 
While the state of international market access may be relatively static, the 
agri-food sector is exhibiting considerable innovativeness and dynamism – the move 
to genetic modification of some plants, the expansion in biofuel production, ongoing 
improvements in cold chain capacity in food supply chains and the arrival of a 
growing range of functional foods – those that provide health benefits beyond those 
arising from those associated with nutrition, to name only a few. Rising consumer 
incomes have led to more value added and processing being incorporated in the food 
people buy and a decline in the proportion of meals eaten at home. As a result, there is 
a greater opportunity to engage in product differentiation in the food sector. The trade 
barriers in the agricultural sector largely reflect the period when international 
movements were largely commodity-based meaning that product differentiation was 
difficult and farmers in one country were competing directly with farmers in another 
country. 
While significant progress on liberalizing market access in agriculture has 
proved allusive over the last half century, the imposition of new barriers has been 
more difficult. As with other tariffs, agricultural tariffs have long been bound and the 
creation of new tariffs largely prohibited. Certainly, some new non-tariff barriers have 
been put in place and the process of tariffication and the establishment of tariff rate 3 
 
quotas that arose from the Uruguay Round led to increases in barriers to access, but, 
for the most part, the barriers to agricultural trade have been long standing. 
Given the changing nature of agri-food products and trade – and the apparent 
inability to garner significant liberalization in multilateral negotiations – the question 
arises as to whether trade barriers put in place decades ago are still appropriate. Are 
there situations where the decision to impose barriers to trade need to be revisited? 
This implies a piecemeal approach to trade liberalization. Of course, countries always 
have the right to unilaterally lower their trade barriers. One suspects that there is a 
great deal of inertia in trade policy making once trade barriers are imposed. Thus, the 
question becomes, when should policy makers revisit the decision to impose trade 
barriers? 
Except under particular market configurations (e.g. optimum tariff strategies 
for large countries), trade restrictions are welfare reducing (Gaisford and Hester, 
2007). As policy makers are willing to impose trade barriers, this suggests that they 
must give implicit, if not explicit, weightings to the benefits (received or forgone) by 
various market participants. In a simple example, if the benefits forgone by consumers 
from the imposition of a trade barrier are three times the value of the benefits received 
by producers, when policy makers chose to impose the barrier then they must, at a 
minimum, give a weighting to producers welfare that is three times that which they 
give to consumers welfare. Of course, it may be that the actual weighting given to 
producer’s welfare is four or five times that which they give to consumers. The 4 
 
tipping point where the marginal weighted utility of consumers is equal to the 
marginal weighted utility of producers, as evaluated by policy makers, is not 
transparent. It is, however, clear that there must be some implicit tipping point where 
a policy decision would be reversed. 
If the benefits forgone from the existence of a trade barrier were to increase 
significantly, or the benefits reaped decreased significantly (or some combination of 
the two) then the tipping point might be reached and policy makers might wish to 
revisit their decision. It is clear that policy makers require additional information upon 
which to base their decisions. 
One of the areas where agri-food products are evolving, and where there may 
have been an increase in the benefits forgone when trade barriers are in place, is 
functional foods. Functional foods provide consumers with health benefits in excess 
of the value provided by the food’s nutrition. In some cases, foods have been 
improved or enhanced to provide the new health benefits; in other cases research has 
found new health benefits in previously existing products. As the barriers to trade in 
food products were put in place when only the nutritional value of the food was 
known, there will be additional benefits forgone. As yet, there are no separate tariff 
lines for functional food variants of traditional products – and creating new tariff lines 
is a long and complicated process (Kerr and Loppacher, 2005). 
This paper has two objectives: (1) to provide a preliminary investigation into 
how the additional benefits expected from functional foods can be incorporated into 5 
 
trade models and; (2) to provide case studies to examine whether the increased 
benefits forgone are of sufficient magnitude to cause policy makers to revisit the 
decision to impose trade barriers. While the latter is subjective, if the results of the 
empirical analysis produce what appear to be trivial changes in the benefits forgone, 
then it might be concluded that this is not an appropriate avenue for further research. 
Given that we do not know of any other attempts to incorporate health benefits into 
trade models, this is an important first step. 
Functional Foods 
New types of foods designed to promote health or to reduce the risk of 
diseases have been recognized as functional foods since the 1990s (Niva and Mäkelä, 
2007). These new products are designed to meet specific health
 concerns by assisting 
disease prevention and helping to promote health. In addition to new products which 
are designed to be health-enhancing, a number of traditional and familiar foods are 
also now considered functional foods as new health benefits have been recently 
discovered (Hasler, 2000). For example, at the annual Frontiers in Cancer Prevention 
Research conference in Seattle 2004, it was pointed out that an apple a day may be an 
effective approach to cancer prevention (Davis, 2004). Eggs have proved to be an 
excellent dietary source
 of many essential (e.g., protein/choline) and non-essential
 
(e.g., lutein/zeaxanthin) elements that promote optimal
 health (Hasler, 2000). 
Consumers are increasingly interested in combining their diet decision with 
the promotion of health benefits. As a result, functional food products represent a 6 
 
value-added growth opportunity for the agri-food industry around the world. 
According to Euromonitor International (2006), the world market for functional foods 
has grown by more than 50 percent in the last 5 years. The United States, Japan and 
Europe are major global markets, contributing over 90 percent of total sales 
(Kotilainen et al., 2006). Healthy food (natural and organic foods, functional foods 
and lesser evil foods
1) sales in the United States reached US $102 billion in 2004. 
Among them, functional foods accounted for 20 per cent of total US healthy food 
sales (excluding food service). The sales of functional and fortified foods were 
expected to reach US $59.87 billion in 2009 (Sloan, 2006). 
Japan is the second-largest market in the world for functional products after 
the US (JETRO, 2006). The Japanese market is valued between US $4 billion and US 
$15 billion annually (SWMI, 2002). The functional food market in Europe is expected 
to grow quickly  —  by as much as 16 percent annually  — reaching  an  approximate 
value US $15 billion (SWMI, 2002). Canada can be an internationally competitive 
producer of a range of functional foods. The small size of the Canadian market, 
however, suggests that the success of the functional foods industry will depend, to a 
considerable degree, on access to foreign markets (Yeung et al., 2007). 
Valuing Health Benefits 
Correct valuation of risks to human health is essential to health, safety, and the 
environment (Berger et al., 1987). A number of broad-based economic approaches to 
                                                 
1  Lesser-evil foods are manufactured by removing unwanted substances including fat, calories, preservatives, 
caffeine, alcohol, salt, etc. from their originally state (NBJ,2008).   7 
 
estimating health benefits have been developed including; cost-illness analysis, 
cost-effectiveness analyses, cost-utility analyses and cost-benefit analyses; while 
partial economic evaluations depend on cost analyses, cost-comparison studies and 
cost-outcome descriptions (Higgins and Green, 2008). Traditionally, measuring the 
benefits of improved health has been based on avoidance of the damage that occurs as 
a result of contracting disease (Berger et al., 1987). One of the simplest and most 
straightforward approaches to estimate the medical costs avoided based on health 
improvements is the cost-of-illness (COI) model (EPA, 1991). Cost of illness studies 
were first used in the late 1950s and early 1960s and have been used extensively since 
that time (Cooper and Rice, 1976). They are most common in the medical literature. 
The basic idea in COI studies is to estimate the maximum economic costs that could 
potentially be saved or gained if a disease were to be lessened or eradicated (Segel, 
2006). The cost of illness is measured by the sum of the direct costs for prevention, 
detection and treatment from health care and the indirect costs or loss due to disability 
(morbidity) and premature death (mortality) (Cooper and Rice, 1976). COI studies are 
valuable because they provide informative evidence for policy makers (Segel, 2006). 
The COI approach has been used to evaluate the benefits of functional foods. 
For example, Malla et al. (2007) valued the potential health benefits of trans fat-free 
canola oil by using the COI model. In their paper, a COI model is adapted to estimate 
the impact of a change in dietary fat intake on coronary heart disease (CHD) costs in 
Canada. Their results have shown that the potential health-care or cost of illness 8 
 
savings in Canada from healthier trans fat-free oils are important. The authors suggest 
valuing health improvements through food industry innovations is a subject worthy of 
further study (Malla et al., 2007). In this paper we adapt this approach to assist in the 
estimation of the foregone benefits of retaining trade barriers.
2 
Trade Policy Trade Offs 
A comparative-static partial equilibrium trade model (Gaisford and Kerr, 2001) 
is illustrated in Figure 1. D is the domestic demand curve for a particular product. As 
the price of the product, P, rises, consumers will not be willing to purchase the same 
quantity as at the lower price. Consequently, the quantity demanded, Q, declines and 
the demand curve is negatively sloped. For supply, as the price, P, rises, production 
becomes more profitable and the output supplied by producers increases. Thus, the 
quantity supplied, Q, increases, leading to a positively sloped supply curve, S 
(Gaisford and Kerr, 2001). Without the opportunity to engage in international trade, 
the equilibrium price is determined where the total domestic supply of the commodity 
                                                 
2  There are, however, weaknesses associated with the use of cost-of-illness studies. As a basic and straightforward 
method, a COI model may overlook additional information that could be used to better value the impact. 
Opportunity costs, for example, should be considered in a health evaluation to obtain the optimal solution for the 
allocation of resources (Donaldson and Narayan, 1998). Another example is the difficulty associated with 
measuring the utility foregone by consumers in a COI model compared to a contingent valuation (CV) model. 
Based on a survey of willingness-to-pay or willingness-to accept among responders, a CV model is superior in 
valuating non-market attributed which give people utility. Without taking into account the loss in utility to 
individuals, the COI model may underestimate the true cost of illness. Furthermore, instead of establishing a 
relationship between costs and benefits, the static COI model simply tabulates the two concepts and adds them 
together to establish the net total cost (Roux and Donaldson, 2004). Without the appropriate information and a 
comprehensive treatment, COI studies are likely to be sub-optimal in determining how resources are to be 
allocated (Drummond, 1992.). 
 9 
 
is equal to the total domestic demand. At this point, E, the market clears at PE because 
the quantity being supplied by firms, Q
E is exactly equal to the quantity of the 
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In Figure 1 in the autarky case, consumer surplus is represented by area a1 
which is a triangle above the domestic price and below the demand curve. Producer 
surplus is area a2+a5+a10, a triangle below the domestic price and above the supply 
curve. Combined, the consumer surplus and the producer surplus, make up the total 
surplus or the welfare arising in this market. 
Now assume the opportunity to engage in international trade in this product 
arises. The price consumers and producers face in the international markets is Pw — 
the world price. In this case, Pw is the price at which imports can be obtained in the 
international market, Pw < PE. Assuming transport and transaction costs associated 
with international shipments are sufficiently small to ignore, the domestic price will 
decline until it is equal to the world price. At Pw, domestic consumers are willing to 
purchase Q
D while domestic producers are only willing to supply Q
S. The difference 
between demand and supply at Pw is filled by imports. The import quantity is shown 
as (Q
D-Q
S). Consumer surplus is a1 +a2 + a3 + a4 + a5 + a6 + a7 + a8 + a9 which is a 
triangle above the world price and below the demand curve. Producer surplus is area 
a10. Total welfare is a1 +a2 + a3 + a4 + a5 + a6 + a7 + a8 + a9 + a10 and greater than 
under autarky (i.e. a1 +a2 + a5 + a10 ). Thus, trade is welfare enhancing. 
If Pw is too low for some producers to make normal profit, they may lobby for 
protection from imports. Political decision makers may wish to supply protection. 
Protection could be provided through the imposition of a tariff (tax) on imports. After 
the tariff, T, is imposed, the domestic price rises from Pw to (Pw + T). At price (Pw + 12 
 
T), domestic firms are willing to produce additional quantity because they must now 
compete with imports priced at (Pw + T) instead of with imports priced at Pw. The 
supply expands from Q
S to Q
S’.
 However, the higher price leads to a reduction in 
consumption from Q
D to Q
D’. Thus, imports decrease to (Q
D’- Q
S’). 
After imposing the tariff, total welfare also changes. The higher domestic 
price leads to an increase in producer surplus but a loss in consumer surplus. At price 
(Pw + T), the consumer surplus shrinks from area a1 +a2 + a3 + a4 + a5 + a6 + a7 + a8 + 
a9  to area a1 +a2 + a3 + a4 and producer surplus increase from area a10 to area a5 + a10. 
The tariff causes a loss of consumer surplus equal to a5 + a6 + a7 + a8 + a9 for a gain in 
producers surplus of a5 . If the objective of the protection policy was to increase 
producer surplus by a5, decision makers must weigh the benefits received by 
producers more heavily than benefits forgone by consumers. In this case, we assume 
that the revenue received by government is not a motivation in the decision to provide 
protection. This is a reasonable assumption for most modern market economies where 
tariffs receipts are a relatively trivial source of revenue
3. In the case of functional 
foods, the trade restricting policies may not be tariffs
4. Thus, the protection is 
assumed to have been granted on the basis of a weighting of consumer and producer 
benefits only. Let us denote η   as the ratio giving decision makers’ weighting of the 
changes in consumer surplus and producer surplus arising from the imposition of a 
protectionist policy. 
                                                 
3  This may not be the case for some developing countries and the analysis would have to incorporate tax revenues 
for those countries. We ignore these cases. 
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Compared to the situation before the tariff, consumers suffer a loss of area a5 + a6 + a7 
+ a8 + a9 and producer gain area a5 . Thus, 
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= η   , Which is larger than 1.   
 
In order to clarify the effects before and after the granting of protection, let us 
simply assume η = 3 for this specific situation. When η =3, the loss for 
consumers arising from the higher price is three times larger than the gain by 
producers. Political decision makers must assign at least three times the weight to 
producer benefits than they assign to consumer benefits. Given that the tariff was 
imposed, a weight of three is the minimum weight they could have used in their 
decision, although a higher weighting may have been possible. While political 
decision makers may not explicitly make these weighed tradeoffs, they must do it 
implicitly with some rule of thumb. The change in trade policy turns out to be welfare 
reducing for the domestic economy (Gaisford and Kerr, 2001). If the situation in the 
market changes such that η rises, a case might be made for decision makers to 
re-evaluate their decisions. 
Trade Barriers and Functional Foods – Four Cases  
This paper focuses on the trade policy effects when new products with health 
improving attributes — functional foods — become available in markets with 14 
 
pre-existing restrictions on trade in place. While the trade barrier in place could be a 
tariff, non-tariff barriers are also common in agriculture (Hobbs, 2007). Food products 
normally face two broad types of non-tariff barriers. One set of non-tariff barriers acts 
like an import ban — prevents any imports. Other non-tariff barriers raise the cost of 
exporting so that imports still take place, but at lower levels — the effect is similar to 
a tariff (Kerr, 2007). 
Figure 2 illustrates the differential effects of a ban compared to an increase in 
costs as a result of an import regulation. Before any import regulation is put into place, 
domestic consumers and producers face Pw, a world price in the international market. 
At Pw, domestic demand from consumers is Q
D while domestic supply is Q
S. The 
difference between demand and supply at Pw leads to imports. The import quantity is 
shown as (Q
D- Q
S). However, when there are non-tariff barriers pertaining to imports, 
the market will be constrained. If the non-tariff barrier acts like an import ban, it 
prevents any imports. There is only domestic production sold in the market and 
imports at Pw cannot take place. The market will clear at PE. The equilibrium quantity 
is Q




















Non-tariff barriers can also raise the cost of exporting. In such a case, the 
domestic price will increase from Pw to (Pw + C) - where C is the additional cost 
increase faced by the exporter in satisfying the importing country’s requirements. At 
(Pw +C), import quantity shrinks to (Q
D’- Q
S’). 
In order to gain market access, exporters may have to satisfy cost increasing 
regulations of importing countries. An example might be testing to ensure that 
imports are free of a drug residue. These regulations may be unduly odorous and thus 
provide economic protection — they are a disguised protectionist measure. Thus, 
there are additional costs incurred in the process of production when firms in the 
exporting country wish to export their products. If there are different requirements for 
testing and proof of scientific evidence, the importing country may refuse to accept 
foreign credentials or scientific procedures and the importer’s regulations are 
equivalent to an import ban. 
The welfare effects of a trade restriction also vary depending on whether or 
not the new functional food can be provided domestically in the importing market. 
Therefore, four different cases pertaining to import restrictions on functional foods 
can be examined. These four cases fall into two categories: trade policy and ability to 
produce. Within trade policy, the focus is on the trade barrier faced by exporters. The 
barrier is either equivalent to an import ban or a cost increasing regulation
5. Under 
ability to produce, functional foods are divided by the ability to acquire the new 
                                                 
5  Tariffs are treated as part of the latter category.   17 
 
products from domestic producers as well as imports (domestic production or imports) 
or solely from imports (imports only). 
Table 1 outlines the four cases under different trade policy and production 
constraints. Case 1 and Case 3 are based on the same trade policy but different 
assumptions regarding the ability to produce. Products in Case 1 can be supplied by 
domestic producers and obtained from the international market. On the other hand, for 
Case 3, the functional food version of the product can only be acquired from the 
international market. In Case 2 and Case 4 the supply choices are the same as above 
but the market is constrained by the more restrictive policy such that imports are 
effectively banned.   
  18 
 
   
 
Table 1: Four Cases for trade policy and the supply of functional foods 
 
 
Cost increasing regulation  Import prohibition 
Domestic production   
or imports 
Case 1  Case 2 











For Case 1, there are both domestic sellers and an international source of 
supply for a new functional food. Figure 3 shows the domestic market of the new 
functional food. D
M is the demand curve for a pre-existing product that does not have 
health enhancing attributes, product M. There is a domestic supply curve S
M for 
product M. At Pw, the world price for M, consumers are willing to purchase Q
DM and 
producers will only supply Q
SM. Imports would be (Q
DM- Q
SM ). If a cost increasing 
import restriction has been put in place that raises costs so that the landed price equals 
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The cost increasing policy will alter welfare in the market. Without the 
regulation, the consumer surplus is area a1 +a2 + a3 + a4 + a5 + a6 + a7 + a8 + a9. 
Producer surplus is shown as area a10. After trade policy is implemented, consumer 
surplus decreased to area a1 +a2 + a3 + a4.    Consumers suffer a loss of area a5 + a6 + 
a7 + a8 + a9 in consumer surplus because of the higher price. On the other hand, 
producer surplus increases to an area a5 + a10 — a change equal to a5. The relative 
weighing ratio is 
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= η  
 
Now assume a new health enhancing functional food version of product M, denoted 
product N, comes onto the market. In order to simplify the exposition, we make three 
assumptions. First, we assume the new product, N, can be produced at the same cost 
as product M by both domestic and foreign suppliers. Second, product N can be 
represented by the same demand curve as product M and that the new health attribute 
does not change the slope of the demand curve in a meaningful way.
6 Thirdly,  from 
the perspective of consumers, more people are willing to buy the new health 
enhancing product N at the same price. Therefore, demand increases shifting out the 
demand curve from D
M to D
N . As the additional demand can be accommodated by 
                                                 
6  It is possible that the slope of demand curve for product N will be changed due to a change in consumers’ 
perception of the product. As no information is available on how the slope may have changed, a parallel shift in 
demand is assumed. 22 
 
acquiring additional imports at (Pw + C), there is no change in price. Thus there is no 
change in domestic producer surplus. 
The new product, N, faces the original world price Pw and distorted landed price (Pw + 
C), the same as with product M. With the new demand curve, consumers receive more 
surplus than that from product M. With no trade restriction, consumer surplus changes 
from area a1 +a2 + a3 + a4 + a5 + a6 + a7 + a8 + a9 to area a1 +a2 + a3 + a4 + a5 + a6 + a7 
+ a8 + a9 +a11 + a12 + a13 + a14 an increased benefit of area a11 + a12 + a13 + a14.  After 
the cost increasing trade policy is applied, new world price (Pw + C) leads to a decline 
in consumer surplus to area a1 +a2 + a3 + a4 + a11 + a12. Therefore, the cost increasing 
policy generates a loss in consumer welfare of area a5 + a6 + a7 + a8 + a9 + a13 + a14. In 
addition to the direct consumer benefits from functional foods which arise in this 
market, there may be savings in health care costs
7  for the government as a result of 
the consumption of the functional food. We assume for the moment that these cost 
savings are a positive constant denoted HCS
8. The relative weighting ratio is now at 
least 
5
14 13 9 8 7 6 5 N HCS                          
surplus producer 
HCS     surplus consumer   
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Therefore,
  η η
M N
    >
 ;  
5
9 8 7 6 5
5
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.
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a
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a
a a a a a a a + + + +
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7  Health care costs include direct health care cost such as inpatient care cost and out patient care cost as well as 
indirect health care costs such as a loss in productivity and the provision of informal care. 
8  This assumption will be relaxed at a later stage. 23 
 






For Case 2, there still exist both domestic producers and international sources 
of supply for a new functional food. However, the new functional food, N, faces a 
regulatory trade barrier that is equivalent to an import ban. 
Figure 4 illustrates the domestic market when a new functional food enters the 
marketplace. As in Case 1, D
M is the demand curve for a pre-existing product that 
does not have health enhancing attributes, product M. S
M is the domestic supply curve 
for product M. At Pw, the world price for M, consumers are willing to purchase Q
DM 
and producers will only supply Q
SM. Imports would be (Q
DM- Q
SM ). The consumer 
surplus is area a1 +a2 + a5 + a6+ a7 + a8 and the producer surplus is area a9.  If there is 
an import ban imposed on product M, the price will rise to P
E
M and the quantity 
consumed will be Q
EM. Therefore, the consumer surplus will decrease to area a1 +a2 
−a reduction of a5 + a6+ a7 + a8. Producer surplus increases to area a5 +a9 with an 
increase equal to area a5. 
The relative weighting ratio is 
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Now product N — a new health enhancing version of traditional food — 
arrives in the market. Our two assumptions still hold: (1) The new version product, N, 
can be produced at the same cost as product M by both domestic and foreign suppliers 
and; (2) more consumers are willing to buy the new health enhancing product N at the 
same price. Therefore, the new health enhancing functional food, N, shifts demand 
curve out to D
N . Product N faces the same world price as product M. At Pw, the 
consumer surplus increases to area a1 +a2 + a3 + a4 + a5 + a6 + a7 + a8 + a10 + a11. As 
the world price is unchanged and the supply curve is not altered, domestic producer 
surplus remain equal to area a9.   
With the import ban in place, the domestic price rises to P
E
N and the quantity 
consumed equals to Q
EN. At P
E
N, consumer surplus decreases to area a1 +a10.  
Consumers suffer a loss of area a2 + a3 + a4 + a5 + a6 + a7 + a8 + a11 in consumer 
surplus because of the higher price. On the other hand, new producer surplus 
increases to a area a2 +a3+ a5 +a9 — a change equal to a2 +a3+ a5.  Again, there may 
also be a health cost savings  — HCS.  The  relative  weighting  ratio  is 
5 3 2
1 1 8 7 6 5   4 3 2 N
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It is an empirical question whether η
N   >  η
M  or  η
N   <  η
M
 or  η
N   =  
η
M
  due to the different producer surplus change in the denominator of our weighting 
ration formula. It is possible that η
N  >  η
M
  . So, policy makers may wish to 




For Case 3, there is only an international supply for a new functional food. 
Figure 5 shows the domestic market of both conventional product and the new 
functional food version of the products. Before the new innovative product enters into 
the market, the situation for the original product M is the same as in Case 1. D
M is the 
demand curve for a pre-existing product M and the supply curve S
M for product M. At 
Pw, the world price for M, imports would be the difference between what consumers 
are willing to purchase, Q
DM, and what producers will supply, Q
SM , that is (Q
DM- 
Q
SM ) . If a cost increasing import restriction has been put in place that raises costs so 




  Figure 5: Case 3 —import supply only, cost increasing regulation 
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The cost increasing policy will change the welfare in the market. Without the 
regulation in place, the consumer surplus is area a1 +a2 + a3 + a4 + a5 + a7 + a8 + a9 + 
a10 + a11 + a12 + a13 + a14 + a15 + a16 and producer surplus is area a6. However, after 
trade policy is implemented, consumer surplus decreased to area a1 + a2 + a3+ a13 + 
a14 with a loss of area a4 + a5 + a7 + a8 + a9 + a10 + a11 + a12 + a15 + a16. In contrast, 
producer surplus increases to area a4 + a5 + a6 + a7 + a8 + a10 — a gain equal to a4 + 
a5 + a7 + a8 + a10.    The relative weighting ratio is 
 
10 8 7 5 4
16 15 12 11 10 9 8 7 5 4 M
           
                                 
surplus producer 
  surplus consumer   
 
a a a a a
a a a a a a a a a a
+ + + +




= η  
 
Now assume the new version of product M — a health enhancing functional 
food N — comes onto the market but can only be sourced from imports. Our 
assumptions: (1) new product, N, can be produced at the same cost as M by foreign 
suppliers and, (2) product N can be represented by a demand curve that has the same 
slope as product M. (3) more people are willing to buy the new health enhancing 
product N at the same price, still apply here. 
To begin with, product M and N are facing the same world price at Pw with 
no trade barrier. At any price above Pw, no consumers are willing to purchase 
product M. Based on the assumptions, consumers switch to the market for N, which 
shifts the demand curve from DM to DM
1 in the market for M. This unambiguous 
switch to product N will continue until curve DM reaches DM
3. The difference 
between demand curve DM and DM
3 leads to a separate market for N. In the market 30 
 
for N in Figure 5, we take DN
1 for the demand curve of product N when the demand 
for product M is DM
3. Once the demand curve for M shifts further to the left of DM
3 , 
product M’s price will be less than Pw and some consumers will choose to continue 
to consume it. This means that the rate at which consumers are switching to product 
N slows. The further to the left the demand curve for M moves, the larger the price 
advantage for product M and the more attractive product M will be to consumers. 
An equilibrium may well be reached somewhere between point D and F in Figure 5. 
If the demand curve for M reaches DM
4 , no firms are willing to supply product M. 
At point F, the market for M no longer exists and all consumers have moved to the 
market for N. 
When there is a cost increasing restriction in place, the demand will again 
shift inward as consumers switch to the more desirable product, N. When demand 
for M reaches DM
1, point A in Figure 5, product M and N both face price（Pw + C). 
The difference between demand curve DM and DM
1 leads to demand curve DN for 
product N in the separate market for N.
 
As the demand curve moves beyond point A, the demand curve of M still 
shifts inward because consumers might be more interested in the new version of the 
product with functional attributes. However, it is possible that domestic producers 
can supply product M at a lower price than (Pw + C). Therefore, some consumers 
may stay in the market for M because it is lower priced than N. Let’s suppose the 
price of M declined to PE
M, where DM
2 equals S
M. Point B, may be an equilibrium if 31 
 
no more consumers are willing to switch to product N. As more consumers switch 
from M to N, the demand curve for N shifts out from DN in Figure 5. Finally, the 
demand curve in market for M could reach DM
4 and the demand curve in market for 
N will move to DN
2 in Figure 5. At point F, there is no supply for product M and 
consumers will all have switched to the market for N.
 
As the demand changes are dynamic, we calculate the welfare of both 
consumers and producers based on minimum changes at point A and for the 
maximum change, point F. In both markets together, consumers receive more 
surplus than that arising from only product M being in the market — N gives more 
utility per unit than M. At point G, without a trade barrier, consumer surplus equal 
area a1 +a2 + a3 + a4 + a5 + a7 + a8 + a9 + a10 + a11 + a12+ b1 + b2+ b4. However, after 
the cost increasing trade policy is applied, at point A, new world price (Pw + C) 
leads to a consumer surplus change equal to area a1 + a2 + a3+ b1 with a loss in 
consumer welfare of area a4 + a5 + a7 + a8 + a9 + a10 + a11 + a12 + b2. The change in 
producer surplus remains a4 + a5 + a7 + a8 + a10.
 
The relative weighting ratio is now at least 
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= η ,  
where only product M is available in the domestic market. 
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As a result, political decision makers may wish to reconsider their decision to 
impose a trade barrier which adds to the cost of imports. 
At point F in Figure 5, without a trade barrier, the demand in market for 
product N has shifted to DN
2 and consumer surplus equals area b1 +b2 + b3 + b4 + b5 
+ b6 + b7  However after the cost increasing trade policy is applied, new world price 
(Pw + C) moves consumer surplus to area b1 + b3 + b6 with a loss in consumer 
welfare of area b2 + b4 + b5 + b7. One the producer side, at point G, the producer 
surplus is a6 before any policy applied. After the cost increasing regulation is 
implemented, at point A, the producer surplus is equal to a4 + a5 + a6+ a7 + a8 + a10 
with a gain of a4 + a5 + a7 + a8 + a10. Nevertheless, the producer surplus is decreasing 
with the movement of the demand curve for M. When the demand curve for M 
moves from DM to DM
2, that is from point A to point B, the producer surplus changes 
to a5 + a6 + a8 with a reduction of a4 + a7 +a10. Compared to the producer surplus 
before product N entered into the market, calculated as a6, however, producers still 
gain a5 + a8 if there is no trade restriction existing in the market.  Once the demand 
curve shifts to point D, the producer surplus returns to a6 which is exactly the same 
as when only product M was available in the market without any trade restriction. 33 
 
Thus, producers do not receive any benefits from the trade restriction policy at point 
D. From Point D to Point F, the producers lose surplus from the arrival of the new 
good in the market. The price increasing policy provides no benefit to producers 
after point D is reached, and consumers suffer a loss in surplus because of the cost 
increasing regulation. Thus, the policy has no merit and should be abandoned.   
 
Case 4 
In Case 4, while there is domestic capacity to supply the conventional 
version of product, no domestic capacity to supply the new functional food exists. 
The new products can only be acquired from the international market. However, the 
new functional food can’t be acquired from aboard because of an import policy that 
is equivalent to a ban. 
Figure 6 give us an insight into the domestic market before and after the 
introduction of a new functional food product. As in the previous cases, D
M 
represents the demand curve for a pre-existing product that does not have health 
enhancing attributes, product M. S
M is the supply curve for product M. At Pw, the 
world price for M, consumers will purchase Q
DM and producers are only willing to 
supply Q
SM. The difference between demand and supply would be (Q
DM- Q
SM ) for 
imports. Thus, the consumer surplus is area a1 +a2 + a3 + a4 and the producer surplus 
is area a5.  As in Case 2, if there is a import ban imposed on the product M, both 
consumers and producers will reach the new equilibrium E
M with P
E
M, a higher price 34 
 
than Pw, and quantity Q
EM. Therefore, the consumer surplus will decrease to area a1 
with a reduction of a2 + a3 + a4. Producer surplus changes to area a2 +a5 with an 













































The relative weighting ratio is 
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If the new health-enhancing product N can be introduced into the domestic 
market successful through imports, there will be a demand shift from the original 
demand curve D
M to D
N . From our previous assumption, product N can be produced 
at the same world price as product M. So, at Pw, there is larger demand, Q
DN, for the 
new product. However, in this case, there is no domestic production of product N 
that can be supplied to the consumers. Thus, total imports are equal to total demand 
Q
DN . The consumer surplus expands to area a1+ a2 + a3 +a4 + a6 + a7. 
However, in Case 4, we assume there exists an import regulation that still 
acts like a ban, thus allowing none of product N into the market. The demand for 
product N cannot be supplied by the international producers. Thus, the new demand 
curve, D
N , does not apply under an import ban. The domestic market has to move 
back to the previous situation with the product in an autarky market. 
We assume there is no supply of the old product M from foreign market — 
the exporter no longer produces product M. Thus, consumers and producers return to 
the domestic price P
E
M. At the autarky equilibrium point, consumer surplus 
decreases to area a1, a reduction of area a2 + a3 +a4 + a6 + a7 and the producer surplus 
is area a2 + a5. There would also be a health care savings equal to HCS. Therefore, 
the relative weighting is 37 
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Therefore, political decision makers may wish to change their trade inhibiting 
policy. 
 
Incorporating Health Care Costs  
In each case, we assumed that the HCS is constant. However, savings in 
health care costs for the government is not likely to be a constant. In most cases, it is 
likely to be some function of the consumption of the particular functional food. For 
our analysis, in each case the HCS that would arise from the remove of the trade 
barrier is a function of the increased consumption of product N. That is, 
 HCS  = ƒ( ΔQ
N ), 
where ΔQ
N is the difference between the consumption of N with a trade barrier and 
that which arises without the trade barrier.   
HCS will be different depending on each case given the different trade 
situations illustrated above. In Case 1, there are both domestic sellers and an 
international source of supply for functional food N. The cost increasing regulation 
increases the import price from Pw to (Pw + C) which leads to a reduction in the 
demand of product N. Thus, the difference between the consumption of N with a 38 
 
trade barrier and that of without a trade barrier is measured by the quantity change 
along the demand curve D
N from (Pw + C) to Pw.  
HCS
1 =  ƒ( ΔQ
N ) =  ƒ(Q
DN - Q
DN’)  
In Case 2, product N faces both domestic and international supply but with a 
regulatory trade barrier that is equivalent to an import ban. The import ban allows no 
supply for product N from the international market. Thus, the difference between the 
consumption of N with a trade barrier and that without the trade barrier is measured 
by the quantity change on the demand curve D




2 =  ƒ( ΔQ
N ) = ƒ (Q
DN – Q
EN)  
In Case 3, there is only an international supply for functional food N. Like 
Case 1, the cost increasing regulation makes the import price Pw increase to (Pw + C) 
which leads to a reduction in the demand of product N. Thus, the difference between 
the consumption of N with a trade barrier and that without the trade barrier is 
measured by the quantity change along the demand curve D
N from (Pw + C) to Pw. 
As the figure in Case 3 is dynamic, the change in consumption of the product N, 
which based on the shift of demand curve D
N , can take on a range of values.   
HCS
3 =  ƒ( ΔQ
N ) =  ƒ( ΔQ




In Case 4, there is no domestic capacity to supply the functional food N. 
However, product N cannot be acquired from abroad because of an import policy 
that is equivalent to a ban. Before the import ban, the consumption of N is based on 
imports only and the import quantity is equivalent to domestic demand which is Q
DN. 39 
 
With the import ban in place, the imports of product N do not take place. Therefore, 
there is no consumption of product N. The change in the consumption of product N 
is just equal to Q
DN. 
HCS
4 =  ƒ( ΔQ
N ) = ƒ (Q
DN - 0)   
This section has developed a partial equilibrium model to examine the 
effects of the introduction of functional foods that provided consumers with positive 
health benefits when pre-existing trade restrictions are in place. While undertaking 
empirical investigations for examples of each of the four cases would have been 
desirable given the different results they predict, limits on time and resources 
allowed for investigations of only two of the cases. As the objective of this 
investigation is only to determine whether incorporating health benefits into 
international trade models is worthy of further study, limiting the investigation to 
only two cases is not major constraint. In what follows, two cases are developed 
using trade restrictions on canola oil. The first study involves the Chinese tariff on 
canola oil and is an example of Case 1. The second study examines the market for 
canola oil in the United Kingdom where market access is blocked by the European 
Union’s import ban on genetically modified products – an example based on Case 2 
developed above.     
Barriers to Canola Oil in China 
Over time, consumers have responded to new scientific information related 
to food consumption by switching their purchases to products with healthier or less 40 
 
harmful components (Malla et al., 2007). Recently, the relationship between 
consumption of trans fatty acids (TFA) and associated heart disease has become a 
hot topic with the public. Coronary heart disease (CHD) refers to the failure of the 
coronary circulation system to supply adequate blood to the heart muscle and 
surrounding tissue. Over 451,000 Americans die of coronary heart disease every 
year (AHA, 2008a). In the United Kingdom, over 100,000 deaths annually are 
attributed to coronary heart disease (BHF, 2007). Scientific studies suggest that 
consumption of trans fat will increase the risk of CHD. The Food and Drug 
Administration (FDA) in the United States ruled that the reporting of trans fat levels 
had to be added to the Nutrition Facts Panel on food labels starting from January 1, 
2006. Identifying saturated fat, trans fat, and cholesterol on the food label provides 
consumers with information so that food choices that help reduce the risk of CHD 
can be made. The revised label was expected to be helpful to people who are 
concerned about high blood cholesterol and heart disease (FDA, 2003). 
This section provides a Chinese case study to examine the potential welfare 
benefits forgone from the existence of trade barriers when a selected product 
becomes a functional food. First, the chapter gives a detailed overview of the 
connection between trans fat and health. Further, the selected product  — canola  oil 
is introduced from two aspects  —  its functional attributes to reduce the risk of 
CHD and its international trade status. Following this introduction, the empirical 
case study of Chinese canola oil is examined according to Case 1 in the framework 41 
 
developed above. The forgone benefits of functional canola oil in China arising from 
the trade barriers  — a  tariff — are  calculated. 
Trans fat and Health   
Trans fat (also known as trans fatty acids) is a specific type of fat formed 
when liquid oils are processed into solid fats like shortening and hard margarine. 
However, a small amount of trans fat is naturally occurring, primarily in selected 
animal-based foods. The majority of trans fat comes from adding hydrogen to 
vegetable oil through a process called hydrogenation. Trans fats are more solid than 
oil but less likely to spoil. In processed foods, trans fat helps food keep fresh, 
extends the self life and gives products a less greasy feel (MFMER, 2006). 
Animal-based fats were once the only trans fats consumed, but by far the 
largest amount of trans fat are formed during the partial hydrogenation of vegetable 
oils, a process that converts vegetable oils into semisolid fats for use in the food 
industry (Mozaffarian et al., 2006). 
The consumption of trans fatty acids raises the levels of low-density 
lipoprotein (LDL) cholesterol
9, so called bad cholesterol and reduces levels of 
high-density lipoprotein (HDL) cholesterol
10, so called good cholesterol. Trans fats 
alter the ratio between LDL and HDL by increasing the ratio HDL in total 
                                                 
9  LDL (bad) cholesterol could lead to heart attack or stroke by forming clots in the inner walls of the arteries and 
blocking the way to feeding the heart and brain (AHA, 2008b). 
10  High levels of HDL (more than 40 mg/dL) protect against heart attack by carrying cholesterol away from the 
arteries to the liver, where it is passed from the body (AHA, 2008b). 42 
 
cholesterol
11. The latter is a powerful predictor of the risk of CHD (Stampfer et al, 
1991). A study published in the New England Journal of Medicine reported that 
trans fat is linked to a 93 percent rise in the risk of cardiovascular disease. The 
research also revealed that replacing of 2% of trans fat consumed with 
monounsaturated fat (MUFA) that are derived from plant sources such as canola, 
peanuts and olives could reduce heart disease risk by 53 percent (Lam, 2002). 
Conventional canola oil and soybean oil require hydrogenation to make them 
stable. Hydrogenation is the process that turns fats into trans fat. New technology, 
however, gives canola oil a very high degree of stability, eliminating the need for 
hydrogenation (Malla et al., 2007). At present, there are two types of canola oil: 
commodity and high-oleic. The former is sold directly to consumers; the latter is 
characterized by high stability which is newer and sold almost exclusively to food 
processing companies and food service operations. Both oils have the same low 
level of saturated fat and positive health attributes (Canola Council of Canada, 
2008a).  
The FDA (2006b) states that:   
Limited and not conclusive scientific evidence suggests that eating about 1½ 
tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart 
disease due to the unsaturated fat content in canola oil. (n.p.) 
 
Thus, Canola oil is seen as a healthier alternative to a number of important vegetable 
oils due to its trans fat-free and very low, or even zero, saturated fat but 
                                                 
11  The total cholesterol to HDL cholesterol ratio is obtained by dividing the total cholesterol value by the value 
of the HDL cholesterol. High ratios (High total cholesterol and low HDL cholesterol) indicate higher risks of 
heart attacks (Kinosian et al., 1994). 43 
 
high—almost 60%—monounsaturated oil content and beneficial omega-3 fatty acids 
profile. Saturated fat has been linked to rising levels of bad LDL cholesterol in the 
blood and increased risk of CHD. Monounsaturated fat is helpful in reducing the risk 
of coronary heart disease and controlling blood glucose by lowering bad LDL 
cholesterol in the blood. Omega-3 fats are essential for a healthy daily diet and it 
helps protect against heart attacks and strokes. Thus, canola oil might be a better 
choice for avoiding trans fat in deep fried and baked foods and is becoming a 
popular oil of choice in restaurants and commercial food products (Canola Council 
of Canada, 2008b). 
The Chinese Vegetable Oil Market  
The market for vegetable oils is growing across Asia as a result of expanding 
populations and rising incomes. China’s population growth rate is approximately 8.6 
million people per year. Further, gross domestic product (GDP) in China has been 
growing at an annual rate in excess of 10 percent. Per-capita GDP in China is 
approximately US$7,600 on a purchasing power parity basis (AAFC, 2007). 
According to the China State Administration of Grain
12, total vegetable oil imports 
reached 8.5Mt in 2006-2007, accounting for 18 percent of global imports of 
vegetable oils. However, the annual consumption of vegetable oils increased to 
23.4Mt, meaning only 15.14Mt are being supplied domestically. The consumption 
of canola oil is 4.34 Mt and domestic production only supplies 4.01 Mt at the 
                                                 
12  State Administration of Grain can be accessed at: http://www.grain.gov.cn 44 
 
existing price level (USDA, 2008). As a result, approximately 0.33 Mt    of canola 
oil are imported. This is approximately to 15% of the world canola oil imports. 
Prior to joining the WTO, China had an import management control system 
for vegetable oils. A tariff rate quota (TRQ) restricted the amount of vegetable oils 
that could be imported. All imports up to the quantity limit known as the TRQ-quota 
were subject to a low within-quota tariff of 9 percent, while any additional imports 
were subject to a higher above-quota tariff ranging between 19.9 percent and 52.4 
percent (Xu and Wang, 2006). From 2006, however, China removed all of the 
import management restrictions on vegetable oils as part of its WTO accession 
commitments. However, there still a flat tariff    of 9 percent on imports of vegetable 
oils. 
In Case 1 developed above, there are both domestic producers and an 
international source of supply for a new functional food. China’s current import 
regime is consistent with the assumptions of Case 1. In the China case study, canola 
oil is a new functional food. Given the constraints on Chinese production and 
processing capacity, imports of canola oil are required. However, the existing tariff 
level    acts as a trade barrier on imports. The protection benefits producers at the 
expense of consumers. This tariff was put in place prior to the health benefits of 
canola becoming apparent. Given that the social costs can be expected to rise as the 
health benefits become known, the Chinese government may wish to revisit having a 
tariff on canola oil. 45 
 
Canola oil is the final consumer product from which the health benefit is 
derived. Of course, canola oilseed is the major traded product. Since the focus of 
this thesis is on the forgone benefits of trans fat free canola oil from existing trade 
barriers, the calculations will not address trade in canola oilseed directly because 
oilseeds are semi-finished products that need further processing into oil and meal. 
The import data used in the Chinese case study are estimated through domestic 
production and consumption for oil – they are net oil import quantities. The benefits 
received by consumers and health care cost savings are derived from oil consumed 
by those living in China.
13 
Stage One – Calculation of Trade Effects    
In Figure 7, D
M is the demand curve for canola oil before people realize the 
health benefits it provided. There is a supply curve S
M for canola oil. At Pw, the 
world price for canola oil, consumers are willing to purchase Q
DM and domestic 
producers will only supply Q
SM. Imports would be (Q
DM- Q
SM ). However, an import 
tariff at 9 percent is in place in China. It raises the domestic price above the world 




Without the tariff, the consumer surplus is area a1 +a2 + a3 + a4 + a5 + a6 + a7 
+ a8 + a9. Producer surplus is area a10. After the tariff is implemented, consumer 
surplus decreased to area a1 +a2 + a3 + a4. Consumers suffer a loss of area a5 + a6 + 
                                                 
13  If one wished to calculate the benefits for exporters, the proportion of trade arising from oil imports and seed 
imports that would be processed into oil would have to be considered. As there is a degree of tariff escalation in 
Chinese tariffs, using the tariff on oil may overestimate the trade benefit to some degree. 46 
 
a7 + a8 + a9 in consumer surplus because of the higher price. On the other hand, 





* In order to calculate the area, a5 is divided into a5a and a5b.  
Figure 7: Chinese Case Study — domestic and import supply with tariff in 
China  
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As canola oil can now be seen as a functional food in the Chinese food 
market due to health enhancing attributes that are newly recognized by the public, 
more people are willing to purchase canola oil. Alternatively, consumers are willing 
to pay a premium for a higher quality (health enhancing) product. Hence, demand 
increases from D
M to D
N .    As the additional demand can be accommodated by 
acquiring additional imports at (Pw + C), there is no change in price. Thus, there is 
no change in domestic producer surplus. 
With the new demand curve, consumers receive more surplus than before. 
With no tariff, consumer surplus changes from area a1 +a2 + a3 + a4 + a5 + a6 + a7 + 
a8 + a9 to area a1 +a2 + a3 + a4 + a5 + a6 + a7 + a8 + a9 +a11 + a12 + a13 + a14, an 
increased benefit of area a11 + a12 + a13 + a14.    After the tariff is applied, new world 
price (Pw + C) leads to a decline in consumer surplus to area a1 +a2 + a3 + a4 + a11 + 
a12. Therefore, the tariff generates a loss in consumer welfare of area a5 + a6 + a7 + 
a8 + a9 + a13 + a14. 
Thus, without new health information regarding canola oil, the direct welfare 
changes arising from the tariff are areas a5 + a6 + a7 + a8 + a9 — the decrease in 
consumer surplus  — and  a5 —  the increase in producers surplus. Both a5 + a6 + a7 
+ a8 + a9 and a5 are trapezoid areas that can be divided into rectangles and triangles 
for the calculation of their values; assuming that over the relevant ranges, the supply 
and demand functions are linear. After health enhancing attributes of canola oil 49 
 
having been accepted, the trade change for consumer is area a5 + a6 + a7 + a8 + a9 + 
a13 + a14 while the increase in producer surplus remains a5.  Area a5 + a6 + a7 + a8 + 
a9 + a13 + a14 can be divided into rectangle a5 + a6 + a7 + a8 + a9 +a13 and triangle a14. 
Combined with the data from Table 2, the calculations and resultant values can be 
found in Table 3. The data sources are provided in Table 2.
14  
                                                 
14  A detailed discussion of the data can be found in Zhang (2009). 50 
 
 
Table 2: Data for the canola/rapeseed oil market in China (2006-2007)
 a 
 
Total consumption (Mt) - Q
DM’ 4.343
 b 
Domestic supply (Mt) - Q
SM’ 4.013
 c 
Supply elasticity -  S ε    0.32 
d 
Demand elasticity -  D ε   -0.20
 e 
World price($ US dollar/tonne) – Pw 852 
f 
Tariff rate  9%
 g 
tariff cost ($ US dollar/tonne) – C  76.68
 h 
Total consumption (Mt) without tariff - Q
DM 4.415
 i 



















a 2006-2007 is from October, 2006 to September, 2007.   51 
 
b Source: United States Department of Agriculture (USDA), Foreign Agricultural Service, July 
2008.  
c Source:
 USDA, Foreign Agricultural Service, July 2008.   
d Note: it is a short-term supply elasticity for national rapeseed supply. (Source: Shen, 2007)   
e Note: it is a direct price elasticity for oilseed oil demand. (Source: Meilke et al., 2001)   
f Average price from October, 2006 to September, 2007. Rotterdam CIF, Any Origin, Oil World. 
Source: USDA, Foreign Agricultural Service, July 2008. 
g Source: China Customs.. 
h Cost - C = P w * 9%.   
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DM) = demand shift rate* (Q
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Table 3: Trade effects in the Chinese Case study
  a5 + a6 + a7 + a8 + a9  a5  a5 + a6 + a7 + a8 + a9 + a13 + a14 
 
Rectangle 
a5 + a6 + a7 + a8 
Triangle a9 Rectangle a5a Triangle a5b 
Trapezoid 
a5 + a6 + 





DM’* C  1/2*( Q
DM - Q
DM’)* C  Q
SM * C  1/2*( Q
SM’ – Q





4.343 * 76.68 
1/2*(4.415- 4.343)* 
76.68 



























Low 369.664 53 
 
Table 3 shows all the calculations and results for the trade effects of canola oil.
15 
With the 9 percent tariff    on imports of canola oil in China, consumers suffer a loss of 
US$335.8 million in consumer surplus    (area a5 + a6 + a7 + a8 + a9) because of the higher 
landed price. On the other hand, producers gain US$303.7 million in producer surplus   
(area a5). 
After health information regarding canola oil becomes well-known to Chinese 
consumers, consumers’ loss increases, but producer gain remains constant. For the four 
levels of demand shift assumed under the sensitivity analysis in appendix 1, a US$403.5 
million in the base case level, a US$505 million in high level, a US$471.2 million in 
medium level and a US$369.7 million loss in low level in consumer surplus change (area 
a5 + a6 + a7 + a8 + a9 + a13 + a14) have been estimated (see Table 3). At the base case level 
of demand shift, for example, consumers suffer a US$403.5 million reduction in 
consumer surplus because of the increased consumption of canola oil. This loss increase 
is approximately 20 percent compared to the former US$335.8 million consumer surplus 
change. For the high level there is approximately a 50 percent increase compared to the 
previous situation. Even at lower levels, increased consumption of healthy canola oil 
leads to a much greater loss in consumer surplus than when the health benefit was 
unknown. As expected, the results of trade effects indicate that the tariff generates a 
larger loss in consumer welfare than the gain on the producer side. The loss becomes 
even larger after the increased consumption of canola oil with health attributes are taken 
into consideration. 
Stage Two – Estimating the Potential Health Care Cost Savings for the Chinese Case 
Study  
                                                 
15  A sensitivity analysis was performed on supply and demand elasticities and the results were found not to be 
particularly dependant on the values used. Details of the sensitivity analysis can be found in Zhang (2009).   54 
 
The model developed by Malla et al. (2007) is adapted to estimate the potential 
health benefit and related medical cost savings in China arising from the consumption of 
more healthy trans fat-free canola oil. They use a variation on the COI approach to 
estimate the impact of a change in dietary fat intake on CHD costs in Canada. Their 
method involves four distinct steps – see Figure 8. The calculation will start from the 
trans fat intake reduction caused by the substitution of a trans fat-free canola oil for other 
vegetable oils to the effect of reduced cholesterol levels on the incidence of CHD in the 
studied country and from there to the relationship between CHD and medical costs 
savings. Following Malla et al. (2007), it is assumed that a 1 percent drop in the 
incidence of the disease in the long run will result in a 1 percent decrease in the COI. 55 
 
 
Figure 8: Steps in a COI analysis 
 
 
(Source: Malla et al., 2007) 
 
Step 1: Estimate possible daily trans fat intake reduction 
due to ‘trans fat-free canola oil in the studied country 
Step 2: Calculate cholesterol change (LDL & HDL) due 
to reduced trans fat consumption 
Step 3: Calculate CHD risk reduction due to changes in 
the cholesterol profile 
Step 4: Calculate health cost changes (HCS) from 
reduced incidence of CHD 56 
 
Step 1: Estimate possible daily trans fat intake reduction due to ‘trans fat-free canola oil 
in China 
In step 1, a total trans fat consumption (intake) per day is estimated using 
available studies. Due to different diets and eating habits, calculations and results vary 
among countries. 
In China, there is no database for TFA consumption.    Generally in China, the 
total fatty acids in the daily diet come from natural fatty acids in food and from vegetable 
based cooking oils that contain very low TFA. On average, the Chinese diet leads to a 
lower intake of shortening oil when compared to diets in North America and Europe. In 
China, however, the growth of fat intake has been dramatic; increasing 2.7 times from 
33g/person/day to 90 g/person/day in the space of a few years (FAO, 2006). With rising 
incomes and the opening of the economy, Chinese dietary tastes are broadening. The 
dietary structure is changing from traditional oriental cooking towards diverse dining. 
North American and European food, and fast food in particular, is becoming increasingly 
popular. While no studies on fat consumption in China could be found, the TFA intake of 
the daily diet in China is increasing due to rising shortening oil consumption, especially 
among young people. 
While no studies on trans fat consumption in mainland China could be found, a 
study on trans fats in locally available foods conducted jointly by the Centre for Food 
Safety (CFS) and the Consumer Council (CC) in Hong Kong, China is available. The 
study tested a total of 80 products which, for the most part, use hydrogenated vegetable 
oils (shortening oil, salad oil and margarine) in their production. Samples included (i) 
bakery products (including breads, cakes, egg tarts, chicken pies and batter-made food 57 
 
such as egg rolls, waffles and egg puffs); (ii) deep fried foods (including French fries, 
fried chicken, pork chops, fritters and pastries); and (iii) butter and 
margarine/margarine-like spreads. The study found that trans fats levels varied 
considerably among similar food products. For example, trans fats levels in 23 bread 
samples ranged from zero to 1.8 g/100 g. Trans fats levels in 11 butter-made products 
ranged from zero to 1.0 g/100 g. For the 14 fried products, there was also a wide range of 
trans fats levels from 0.034 to 0.38 g/100 g. These results suggest that it is possible to 
reduce trans fats levels in food products (CFS, 2007). 
Following the CFS (2007) study, a total trans fat consumption (intake) per day in 
daily food sources can be estimated. The estimated average consumption used in the case 
study on China is 1.99 g, including 0.54 g/day from baked goods and 0.03 g/day from 




                                                 
16The main TFA intake in China is assumed from the above categories - baking, butter-made fried products and 
margarine/margarine like spreads. The average calculation method was used for TFA intake in each category. For 
details, see Section A2.1 in Appendix 2.   58 
 
Table 4: Trans fatty intake reduction in China due to trans-fat-free canola oil   
 
 Base  High Medium  Low 
Total TFA intake daily (g) in sample foods 
a 1.99  1.99 1.99 1.99 
Assumed TFA reduction (%) in sample foods 
b 20  50  40  10 
Total TFA reduction (g) in sample foods
c 0.40  0.99  0.79  0.20 
a The Total TFA intake daily (g) in sample foods is calculated in Section A3.1 in Appendix 3.   
b TFA reduction (%) in sample foods is assumed to have four levels from high, medium, and base to 
low. These four levels indicate the percentage of vegetable oils found in daily food consumption that 
is assumed to be replaced by trans fat-free canola oil. The TFA reduction ratio guarantees the 
subsequent calculations focus solely on the health care cost savings for a certain group of people who 
consumed trans fat-free canola/rapeseed oil rather than other vegetable oils. 




From Table 4, the effect of trans fat-free canola oil substitution can be seen. 
Using sensitivity analysis, the estimation assumes four level of substitution from base 
(20%), high (50%), medium (40%) and low (10%). The resulting reductions in trans fat 
consumption are 0.40 g (Base), 0.99 g (High), 0.79 g (Medium) and 0.20 g (Low) daily in 
China.  
Step 2: Calculate cholesterol change (LDL & HDL) due to reduced trans fat consumption 
According to Malla et al. (2007), a number of studies have measured the effects of 
TFA consumption on LDL, HDL, and total cholesterol levels using controlled diets. 
Following Malla’s conclusion, in step 2, the assumption is made that for every 1 g 
reduction in TFA, total cholesterol will reduced by 1.55 percent. 
Step 3: Calculate CHD risk reduction due to changes in cholesterol profile 
Drawing on the conclusions of the US National Cholesterol Education’s Expert 
Panel (Expert Panel, 1988), the assumption can be made that there is a 2 percent 
reduction in the risk of CHD for every 1 percent reduction in cholesterol levels for the 
medium, base and low cases, while for the high level a 3 percent reduction in CHD risk is 
assumed (Malla et al., 2007).   
Step 4: Calculate health cost changes from reduced incidence of CHD 
The final step in the analysis (step 4) is to calculate the potential health-care cost 
savings from trans fat-free canola oil. 
According to the World Health Organization (WHO), globally, cardiovascular 
diseases were the number one cause of death in the past and remain so currently. An 
estimated 17.5 million people died from cardiovascular disease in 2005, which accounts 
for 30 percent of all global deaths. By 2015, an estimated 20 million people will die from 60 
 
cardiovascular disease (mainly from heart attacks and strokes) if current trends continue 
(WHO, n.d.). In China, the annual deaths due to cardiovascular disease are about 3 
million, accounting for 45 percent of total deaths in the population (NCCD, 2005). 
Treatment of cardiovascular-related diseases is also a major cost in China. In a 
Chinese government cardiovascular report, it was estimated that in 2003, the direct 
cardiovascular disease expense
17  accounted for 16.13 percent (RMB 92.6 billion, 
approximate US $13.2 billion
18) of total health care costs. According to the prediction in 
the report, CHD costs have increased at an average annual growth rate of 12.83 percent 
over the last 10 years. Currently, CHD costs are ranked in the second place in the total 
medical expense in China. The overall health care costs for CHD is approximately RMB 
26.4 billion (US $3.85 billion) with RMB 13.3 billion (US $1.94 billion) for outpatient 
care
19  and RMB 13.1billion (US $1.91 billion) for inpatient care (NCCD, 2005). Due to 
absence of indirect health care costs data for China, the health care costs for CHD 
calculated for this case study are limited to only the direct health care costs including 
outpatient and inpatient care costs. 
In order to simplify the calculation, the estimated cost of illness savings under 
trans fat-free vegetable oil substitution are limited to savings only from cardiovascular 
disease. Other possible health improvements from reduced consumption of TFA are not 
considered in this case study. Following Malla et al. (2007), a 1:1 ratio is assumed 
between reduced CHD risks and health-care cost savings for first three levels; thus, the 
related costs will be decreased by 1 percent if CHD is reduced by 1 percent. For the low 
                                                 
17  Direct costs of CHD represent the value of resources spent that could have been used for other purposes in the 
absence of illness (e.g., hospital expenditures, drug expenditures, medical care, and research) (Malla et al, 2007). 
18  I use USD: CNY = 1:6.86, based on the current market foreign exchange rate (2:00pm, July 7, 2008). These 
exchange rates apply for all exchange calculations between US dollar and Chinese Yuan in this thesis. 
19  Outpatient care includes outpatient care, emergency medical treatment and medications.   61 
 
level, it is assumed that for every percentage reduction in CHD, cost will only be reduced 
by half a percent (Malla et al., 2007). The calculation for health care savings concentrate 
solely on the expansion quantities in the market due to trade liberalization, a HCS rate (%) 
is introduced into the last step calculation ( For details, see section A2.2.1 in appendix 2). 
In Table 5, the total change in annual CHD cost due to trans fat-free canola oil 
substitution is calculated. A range of scenarios are calculated given the incomplete nature 
of the data on HCS. These scenarios are based on Malla et al. (2007). 
The base case estimation assumes that 20 percent of the hydrogenated vegetable 
oils market is replaced by trans fat-free vegetable oils, leading to a 0.40g daily trans fat 
intake reduction in China. With the assumed 1:2 cholesterol to CHD risk ratio it provides 




Table 5: Potential health care savings estimated in China   
 
 Base  High  Medium    Low 
TC change due to 1 g TFA reduction daily(%)
a  1.55  1.55 1.55 1.55 
Daily TFA reduction (g)  0.40  0.99  0.79  0.20 
Total change in TC (%)
b  0.62  1.53 1.22 0.31 
TC to CHD ratio
 c  2.0  3.0 2.0 2.0 
Change in CHD (%)
d  1.24  4.60 2.45 0.62 
Change in CHD (%) to change in cost (%)    1 : 1  1 : 1  1 : 1  1 : 0.5 
Total annual CHD cost($ million US dollars)
e  3850  3850 3850 3850 
Total change in annual CHD cost due to TFA 
reduction in daily diet 
($ million US dollars)
 f 
48 177  94  12 
Health Care Savings (HCS) rate
 g  1.66%  1.65% 1.66% 1.66% 
Final HCS
 ($ million US dollars)
 h  0.79  2.92 1.56 0.20 
a Total Cholesterol (TC) change is rated at 1.55: 1 due to 1 g of TFA reduction. 
b Total change in TC (%) = TC change due to 1 g TFA reduction daily(%) * Daily TFA reduction (g) 
c The relationship between total cholesterol and CHD is 1:2 based on Expert Panel (1988). For the 1:3 
ratio is used for high level estimation which assumed to be the long-term ratio. (Source: Malla et al., 
2007) 
d Change in CHD (%) = total change in TC (%) * TC to CHD ratio   
e Source: NCCD (2005).     
f Total change in CHD cost = total annual CHD cost * Change in CHD(%) * Change in CHD (%) to 
change in cost (%) ratio 
g See Section A2.2.1 in Appendix 2 for details. 
 
h HCS = Total change in annual CHD cost * HCS rate (%) 63 
 
The high level assumption is based on an optimistic perspective that trans fat-free 
vegetable oils cover a 50 percent market share in hydrogenated vegetable oils such as the 
shortening and the salad oil, accounting for a 0.99g trans fat intake reduction daily in 
China. With the assumption that every percentage change in total cholesterol leads to a 3 
percent change in CHD and 1:1 ratio between the incidence of CHD and the resulting 
costs to society, high level estimation results in a saving of about US $2.92 million in 
Chinese health care costs. 
For medium estimate, trans fat-free vegetable oil is assumed to substitute 40 
percent of the hydrogenated vegetable oils market, which together results in a 0.79g trans 
fat intake reduction daily in China. Given a smaller ratio with every percentage change in 
cholesterol level which lead to a 2 percent reduction in CHD, this results in a saving of 
about US $1.56 million in health care costs annually in China based on an assumed 1:1 
ratio between the incidence of CHD and the resulting costs to society. 
The low scenario demonstrates potential health-care cost savings under very 
conservative assumptions. Trans fat-free oils are assumed to reach only a 10 percent 
market share in the hydrogenated vegetable oils market. There is a 0.20g trans fat intake 
reduction daily in China. Besides, a reduced ratio with 1:0.5 is applied between CHD 
change and health-care costs instead of the former 1:1 ratio. Although every step is 
extremely conservative, the low scenario still suggests a potential reduction of about US 
$0.2 million in health-care and medical costs annually in China.   
Stage Three – Determine the Final Ratios for the Chinese Case Study 
Putting a tariff in place changes total welfare. If the objective of the protection 
policy was to increase producer surplus, decision makers must weigh the benefits of 64 
 
producers more heavily than benefits of consumers. As derived above, the ratio η  will 
be applied here to show decision makers’ weighting of the changes in consumer surplus 
and producer surplus as well as the health cost savings arising from the imposition of a 
tariff on canola oil imports in China. Table 6 shows the calculations undertaken to derive 
the ratios used in the comparison. From the table, the ratios for canola oil are calculated 
based on the results from the previous sections. In summary, in the absence of the 
information pertaining to the health benefits from canola, η
M
=1.11. With the health 
benefits, this ratio rises to 1.33 in the base case, 1.67 in the high case, 1.56 in the medium 
case and 1.22 in the low case. 
Considering health benefits and health care cost savings on canola, the weighting 
ratio is considerably larger than before the health benefits of canola oil became known. 
At the base level with 20 percent TFA reduction in daily trans fat intake, the loss for 
consumers arising from the higher price is nearly one and a half times larger than the gain 
by producers. The high and medium levels even show over one and a half times weight 
given to producer benefits relative to consumer benefits. At the low level, consumers still 
lose more than the gain for producers. Therefore, from a welfare perspective, political 




Table 6: Final Ratio Calculation for the Chinese Case Study 
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The Effect of the EU Import Ban on Canola for the United Kingdom 
The UK case study examines the potential welfare benefits forgone from the 
existence of trade an import ban when canola oil becomes a functional food. First, the 
GMO import ban is discussed. Following this introduction, the empirical case study of 
canola oil in the UK is examined as an example of Case 2 in the framework developed 
above. The forgone benefits of functional canola oil in UK arising from the GMO ban 
are then calculated. 
The Import Ban on GMOs  
In recent years, the vegetable oil market in the EU has changed dramatically 
and is now strongly driven by the demand for biodiesel. As a result, there 
is competition between vegetable oil used as an input to biodiesel and for human 
consumption (Bendz, 2007; Gunstone, 2001). 
While the domestic market is expanding rapidly, the import market for canola 
oil is heavily constrained. The EU has had community-wide legislation on genetically 
modified organisms (GMOs) since 1998. Before being placed on the market, GMOs 
must first undergo a very strict assessment process. If approved, they must be labeled 
and managed in accordance with strict product traceability requirements (EUROPA, 
n.d.). The majority of products that use genetic modification technology in their 
production, especially imported products, could not enter into the market because of a 
stringent science-based assessment and a lengthy approval process. GMOs are a 67 
 
contentious political issue in the EU, which delayed the establishment of an 
expeditious approval mechanism and continues to inhibit approvals (Phillips, 2006). 
Europeans preferred the name oilseed rape, rape oil, or rapeseed oil to the 
name canola. One unique difference, however, is that Europe does not permit the 
making of canola oil from genetically modified plants (VitaminsDiary, n.d.). 
European farmers are prevented by law from growing genetically modified rapeseed. 
However, over the period since 1995 about 80 percent of the canola grown in Canada 
has now been modified using biotechnology to make it tolerant to some herbicides 
(Canola Council of Canada, 2008c). Thus, Canadian canola is currently banned from 
the European food market as the GM varieties of canola have not been approved for 
import into the EU and there is no segregation of GM and non-GM canola in the 
post-harvest supply chain (Smyth et al., 2006). Australia was the only major exporter 
of non-GM canola to the EU, but Australia is now adopting GM canola at a rapid rate. 
In the face of pressure from major GM grain exporting countries, the EU has 
made some concessions on the imports of GM products. In late 2004, some GM grain 
varieties were approved but imports of the most important varieties of GM canola are 
still not allowed (Foster and French, 2007). In 2006, the European Commission 
announced that three oilseed rapes known as Ms8, Rf3 and Ms8xRf3 that are 
genetically modified for tolerance to the herbicide glufosinate-ammonium are 
authorized to be placed on the EU market. These oilseed rapes are allowed to be 
imported but only for processing into animal feed or for industrial purposes, not for 
cultivation (EUROPA, 2007). They cannot be imported if destined for the human food 68 
 
supply channel. Thus, the EU market including the UK is effectively closed to canola 
imports that can enhance human health. 
The UK Rapeseed Oil Market 
Both domestic producers and international sources of supply are assumed for a 
new functional food in Case 2 of the framework developed above. In Case 2, the new 
functional food faces a regulatory trade barrier that is equivalent to an import ban. 
Canola oil from Canada suffers from a GMO import ban which prevents market 
access to the U.K and, hence, is a suitable example for a case study under the 
assumptions contained in Case 2
20. 
The European Union is a major producer of rapeseed. In the past, it has been a 
net exporter of rapeseed products. The EU’s net exports have declined in recent years 
and the EU is now becoming a net importer of both rapeseed and rapeseed oil due to 
strong demand for it as an input to biodiesel production (Foster and French, 2007). 
However, the increased imports of rapeseed and rapeseed oil are still small relative   
to the large domestic production  —  approximately 5 percent of domestic production 
in 2006 (see Table 7). Further, the EU has diverted more than three million tonnes, or 
60 percent, of its rapeseed oil production to biodiesel production (Business Times, 
2008). More than half of the imports went to biodiesel production in order to satisfy 
mandated increased utilization of this new transport fuel. Thus, the remaining imports 
of rapeseed oil for food use from other countries only cover a tiny portion of the 
domestic market for rapeseed oil consumption. Thus, it is assumed for the purpose of 
                                                 
20  The assumption being made is that any small remaining quantities of non-GM imports of canola provided from 
Australia can be safely ignored.   69 
 
this case study that the EU, and hence the UK, are closed to cheaper international 
sources of canola oil. 
With its trans fat-free health enhancing attributes, it is assumed that canola oil 
as a functional food will have increased in popularity in the EU market if consumers 
have access to the functional product. However, since the EU has established very 
strict laws governing the import of GM canola, opportunities in promoting health 
benefits may be lost while GM canola imports are prohibited. Hence, in the UK case 
study, imports of rapeseed oil from countries outside the EU are assumed to be to be 
zero in order to better capture the foregone benefits arising from the GMO ban.   
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  Table 7: EU - supply and disposal of rapeseed oil (Kt) 
Source: US Department of Agriculture (2006). 
 
  2002-2003 2003-2004 2004-2005 2005-2006 
Opening 
Stocks 
320 315 152 200 
Production  4353 4339 5365 5945 
Imports 7  33  38  335 
Total  supply  4680 4687 5555 6480 
Domestic 
Consumption  
4115 4392 5365 5945 
Exports  250 143 125  75 
Closing  stocks  315 152 200 190 71 
 
Stage One – Calculation of Trade Effects  
In Figure 9, D
M is the demand curve of canola oil in the UK market prior to the health 
improvement benefits becoming apparent. There is also a supply curve S
M for canola 
oil. At Pw, the world price for canola oil, consumers are willing to purchase Q
DM and 
domestic producers will only supply Q
SM. Imports would be (Q
DM- Q
SM ). However, 
there is a GMO ban in the UK imposed on the import of canola oil for human 
consumption. Therefore, it raises the price to P
E




Without the GMO import ban, the consumer surplus is area a1 +a2 + a5 + a6+ 
a7 + a8. Producer surplus is area a9
22. After the GMO import ban is implemented, 
consumer surplus decreases to area a1 +a2 with a reduction of a5 + a6+ a7 + a8. 
Producer surplus increases to area a5 +a9 with an increase equal to area a5. 
 
                                                 
21  Note we are assuming that the S
M curve includes any transfers within the EU’s single market.   
22 Given  that  S
M includes within EU transfers, the estimates of producer surplus may exceed the value of producer 
























* For calculation purposes, a5 is divided into a5a and a5b .a3 is divided into a3a and a3b. 
 
Figure 9: Case 2 — domestic and import supply, 










































Canola oil can now be viewed as a functional food in the food market in the 
UK. As a result, more people are willing to buy canola oil given its newly recognized 
health enhancing attributes  —  only recognized after the GM import ban was put in 
place. In addition, consumers are expected to be willing to pay at least the same price 
or a premium for higher quality (health enhancing) canola. Therefore, the increased 
consumption of new health enhancing canola oil shifts the demand curve out to D
N . 
Faced with the same world price at Pw, the consumer surplus increases to area a1 +a2 + 
a3 + a4 + a5 + a6 + a7 + a8 + a10 + a11. As the world price is unchanged and the supply 
curve is not altered, domestic producer surplus remain equal to area a9. 
With the import ban in place, however, no imports of canola oil exist in the 
domestic market in the UK. Hence, the domestic price P
E
M rises to P
E
N and the 
quantity consumed equals Q
EN with the increased demand. With higher price P
E
N, 
consumer surplus decreases to area a1 +a10. Consumers suffer a loss of area a2 + a3 + 
a4 + a5 + a6 + a7 + a8 + a11 in surplus because of the higher price. On the other hand, 
producer surplus increases to area a2 +a3+ a5 +a9 — a change equal to a2 +a3+ a5. 
Thus, before any new health information on canola oil was received, the trade 
changes are areas a5 + a6 + a7 + a8 — the decrease in consumer surplus and a5 — the 
increase in producers surplus. Both a5 + a6 + a7 + a8 and a5 are trapezoid areas that can 
be divided into rectangles and triangles for the calculation of their values
23. After the 
health enhancing attributes of canola oil having been recognized by the consumers, 
                                                 
23  Assuming, of course, linear supply and demand curves. 74 
 
the trade change is area a2 + a3 + a4 + a5 + a6 + a7 + a8 + a11 in consumer surplus and a2 
+a3+ a5 in producer surplus. Area a2 + a3 + a4 + a5 + a6 + a7 + a8 + a11can be divided 
into rectangle a2 + a3 + a4 + a5 + a6 + a7 and triangle a8 + a11. Area a2 +a3 can be 
divided as rectangle a2 +a3a and triangle a3b. Combined with the data from Table 8, the 
calculations and resultant values can be found in Table 9. 
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Table 8: Data for canola oil market in the UK (2006)
 a 
 
Total domestic consumption/supply (Mt) – Q
EN b 0.63 
c 
Supply elasticity -  S ε    0.84 
d 
Demand elasticity -  D ε   -0.50
 e 
Average world price($ US dollars/tonne) - Pw  553 
f 
Current domestic price($ US dollars/tonne) – PN
E   983
 g 
Domestic demand (Mt) without GMOs ban- Q
DN 0.77 
h 









Original domestic consumption (Mt) at PM
E - Q
EM 












domestic consumption (Mt) at Pw - Q
DM  m  Base 0.53
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a All the data period is based on year 2006. 
 
b Different from the Chinese case study in the chapter 4, rapeseed oil has been well-known for its 
trans fat-free and other health enhancing benefits in the UK market for over 10 years. Thus, it is 
assumed that the total domestic consumption/supply of rapeseed oil is Q
EN. That means the 
demand curve D
M has already been shifted to D
N in the current market. The initial price for the 
purpose of calculation is, hence, PN
E. 
c Source: FEDIOL(2006).   
d Note: it is a oilseed area response elasticity for oilseed oil supply. (Source: Meilke et al, 2001)     
e Note: it is a direct price elasticity for oilseed oil demand. (Source: Meilke et al, 2001) See   
f Average Pw is based on period from 87/88 to 05/06. Source: USDA (1999) and USDA (2008).   
g Raw vegetable oil price in Netherlands and Germany. Source: Horváth (2006). 
(Origin: 162,663 HUF. Convert to US $ 982 based on 1:0.006042 (HUF: USD) currency rate. 
Source: Yahoo Finance, Sept 27th , 2008.)     
h Q
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j. Demand increases are estimated from current reports and studies regarding to the UK’s 
functional food market. For details, see Appendix 1.2.   
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Table 9: Trade effects calculation in the UK Case study   
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Base  72.48  3.78 60.4  6.04 133.92 20.93  66.44 
270.9 30.1 
High  16.8 0.2  16  0.4  163.8  40.95  16.4 
Med  43.2 1.44  38.4  2.4  150.3  30.06  40.8 
Low  123.38 9.4  94  14.69  102.38  10.24  108.69
Base  76.26 66.44  221.29 
301 
High  17 16.4  221.15 
Med  44.64 40.8  221.16 
Low  132.78 108.69  221.31 79 
 
Table 9 shows all the calculations and results for the trade effects of canola 
oil.
24  With a GMO ban on imports of canola oil in the UK, consumers suffer losses 
ranging from US$17 million to US$133 million at our different levels for consumer 
surplus change (area a5 + a6 + a7 + a8). On the other hand, producers gain US$16.4 
million to US$108.7 million in producer surplus change (area a5). 
After health information regarding canola oil becomes well-known to the 
public, consumers’ loss increases relative to producers’ gain. A US$301 million loss 
in consumer surplus (area a2 + a3 + a4 + a5 + a6 + a7 + a8 + a11) has been calculated 
(see Table 9). Without sufficient imports, increased consumption of canola oil raised 
the domestic market price leading to the loss in consumer surplus. This loss is 
increased substantially compared to former loss in consumer surplus at the four 
different levels. Even at base levels with the US$221 million gain in producer surplus, 
the increased consumption of healthy canola/rapeseed oil leads to a greater loss in 
consumer surplus than when the health benefit was unknown. Although the producer 
surplus also increased (area a2 + a3 + a5), the comparative increase is less than the 
decline in consumer surplus. 
Stage Two – Estimating the Potential Health Care Cost Savings for the UK Case 
Study  
The model developed by Malla et al. (2007) is adapted to estimate the 
potential health benefit and related medical cost savings arising from the consumption 
of more healthy trans fat-free canola oil in the UK. The calculations involve four 
steps. 
                                                 
24  A sensitivity analysis was performed on supply and demand elasticities and the results were found not to be 
particularly dependant on the values used. Details of the sensitivity analysis can be found in Zhang (2009). 80 
 
 
Step 1: Estimate possible daily trans fat intake reduction due to ‘trans fat-free canola 
oil in the UK 
In step 1, a total trans fat consumption (intake) per day is estimated using 
available studies. Hulshof et al. (1999) studied the intake of fatty acids in Western 
Europe. They found that in the United Kingdom, the main sources of TFA were 
partially hydrogenated oils and fats which contribute 35 percent of the intake of total 
trans fatty acids in the diet. Of these, margarines, spreads, frying and cooking fats and 
oils contributed at least 31 percent TFA in the diet. The study further revealed that a 
total daily intake of individual trans fatty acids among 11 fatty acid isomers from 
selected food sources per day is 40.92g in the UK.
25 
The effect of trans fat-free canola oil substitution can be seen in Table 10. 
Using sensitivity analysis, the estimation assumes four level of substitution from base 
(20%), high (50%), medium (40%) and low (10%). The resulting reductions in daily 
trans fat consumption are 0.89 g (Base), 2.22g (High), 1.78 g (Medium) and 0.44 g 
(Low) in the UK.   
 
                                                 
25  11 fatty acid isomers are C14 :1t9 (0.11 g methylesters/day), C16 :1t9 (0.18 g methylesters/day), C18 :1t (2.00 g 
methylesters/day), C18:2t (0.28g methylesters/day), C18:3t+C20:1 (0.17g methylesters/day), C20:2t11,14 (0.02 g 
methylesters/day), C22:1t (0.06 g methylesters/day), C18:1c9 (19.3 g methylesters/day), C18:2c9,12 (11.4 g 
methylesters/day), C18 :3c9,12,15 (1.4 g methylesters/day), C18:0 (6.0 g methylesters/day).   




Table 10: Trans fatty intake reduction in the UK due to trans-fat-free canola oil 
 
a Source: Hulshof et al. (1999). 
b According to Hulshof et al. (1999), the main sources of TFA were partially hydrogenated oils and fats 
which contribute 35 percent of the intake of total trans fatty acids in the diet. Of these, margarines, 
spreads, frying and cooking fats and oils contributed at least 31 percent TFA in the diet. Thus, a 
contribution rate is applied to reveal total TFA intake due to hydrogenated oils consumptions. 
Contribution rate (%) is calculated from the product of 35% times 31%. 
c TFA intake due to hydrogenated oils consumptions = Contribution rate * total TFA (intake) per day 
d TFA reduction (%) in sample foods is assumed have four levels from base, high, medium to low. 
These four levels indicates the percentage of vegetable oils found in daily food consumption that is 
assumed to be substituted by trans fat-free canola oil. The TFA reduction ratio guarantees the 
subsequent calculations focus solely on the health care cost savings for a certain group of people who 
consumed trans fat-free canola/rapeseed oil rather than other vegetable oils. 
e The total TFA reduction = The Total TFA intake daily (g) * Assume TFA reduction (%). 
base High  medium  Low 
Total daily TFA (intake) per person (g)
 a  40.92 40.92  40.92  40.92 
Contribution rate (%)
 b  10.85 10.85  10.85  10.85 
TFA intake due to hydrogenated oils 
consumption 
c 
4.44 4.44  4.44  4.44 
Assume TFA reduction (%)
 d  20 50  40  10 
Total TFA reduction (g)




Step 2: Calculate cholesterol change (LDL & HDL) due to reduced trans fat 
consumption 
According to Malla et al. (2007), a number of studies have measured the 
effects of TFA consumption on LDL, HDL, and total cholesterol levels using 
controlled diets. Following Malla’s conclusion, in step 2, the assumption is made that 
for every 1 g reduction in TFA, total cholesterol will reduced by 1.55 percent. 
 
Step 3: Calculate CHD risk reduction due to changes in cholesterol profile 
Drawing on the conclusions of the US National Cholesterol Education’s 
Expert Panel (Expert Panel, 1988), the assumption can be made that there is a 2 
percent reduction in the risk of CHD for every 1 percent reduction in cholesterol 
levels for the medium, base and low cases, while for the high level a 3 percent 
reduction in CHD risk is assumed (Malla et al., 2007).   
 
Step 4: Calculate cost changes from reduced incidence of CHD 
The final step in the analysis is to calculate the potential health-care cost 
savings from trans fat-free canola oil in the UK. Each year cardiovascular disease 
causes over 4.3 million deaths in Europe and over 2.0 million deaths in the European 
Union which accounts for nearly half of all deaths (Allender et al., 2008a). 
Cardiovascular disease (CVD) leads to larger economic and human costs for Europe. 83 
 
From European cardiovascular disease statistics provided by European Heart Network, 
CVD costs the health systems of the EU about € 110 billion (US$172.7 billion)
26 in 
2006, which represents around 10 percent of the total health care expenditure across 
the EU (Allender et al., 2008a). Further, production losses from CVD deaths and 
illness are also considered into the overall CVD costs leading to a cost of € 192 billion 
(US$301.44 billion) a year. CHD accounts for one-quarter of these overall costs 
(Allender et al., 2008a). In the United Kingdom, the total costs of CHD are 
approximate £9.0 billion (US$17.82 billion)
27  in 2006. Of the total cost of CHD to 
the UK, around 36% is due to direct health care cost, 43% to productivity losses, and 
21% to the informal care of people with CHD (Allender et al., 2008b). 
In order to simplify the calculations, the estimated cost of illness savings 
under trans fat-free vegetable oil substitution are limited to savings only from 
cardiovascular disease. Any other possible health improvements from reduced 
consumption of TFA are not considered in this study. Following Malla et al. (2007), a 
1:1 ratio is assumed between reduced CHD risks and health-care cost savings for the 
first three levels; thus, the related costs will be decreased by 1 percent if CHD is 
reduced by 1 percent. For the low level, it is assumed that for every percentage 
reduction in CHD, cost will only be reduced by half a percent (Malla et al., 2007). 
The health care savings are limited to the opportunities for increased consumption 
arising from trade liberalization, a HCS rate (%) is introduced into the last calculation 
step ( For details, see section A2.2.2 in appendix 2). 
                                                 
26  I use EUR: USD = 1:1.57, based on the current market foreign exchange rate (2:00pm, July 7, 2008).   
27  I use GBP: USD = 1:1.98, based on the current market foreign exchange rate (average, July 7, 2008). 84 
 
 
Table 11: Potential annual health-care savings estimated in the U.K 
 
 Base  High  Medium  Low 
TC change due to 1 g TFA reduction 
daily (%)
a 
-1.55 -1.55 -1.55 -1.55 
Daily TFA reduction  0.89  2.22  1.78  0.44 
Total change in TC (%)
b 1.38  3.44  2.76  0.68 
TC to CHD ratio 
c 2.0  3.0  2.0  2.0 
Change in CHD (%)
d 2.76  10.32  5.52  1.36 
CHD to cost ratio  1.0  1.0  1.0  0.5 
Total annual CHD cost   
(million U.S dollars)
 e 
17820 17820 17820 17820 
Total change in annual CHD cost due to 
TFA reduction in daily diet   
(million US dollars)
 f 
492 1839 984  121 
Health Care Savings (HCS) rate
  g         22%  22% 22%  22% 
Final HCS
 (million US dollars)
 h 108.24  404.58  216.48  26.62 
a Total Cholesterol (TC) change is rated at 1.55: 1 due to 1 g of TFA reduction. 
b Total change in TC (%) = TC change due to 1 g TFA reduction daily(%) * Daily TFA reduction (g) 
c The relationship between total cholesterol and CHD is 1:2 based on Expert Panel (1988). For the 1:3 
ratio is used for high level estimation which assumed to be the long-term ratio. (Source: Malla et al., 
2007) 
d Change in CHD (%) = total change in TC (%) * TC to CHD ratio   85 
 
e Source: Allender et al., (2008b).   
f Total change in CHD cost = total annual CHD cost * Change in CHD(%) * Change in CHD (%) to 
change in cost (%) ratio 
g See Section A2.2.2 in Appendix 2 for details. 
 
h HCS = Total change in annual CHD cost * HCS rate (%) 
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In Table 11, the total estimated change in annual CHD cost in the UK due to 
trans fat-free canola/rapeseed oil substitution is calculated. A range of scenarios are 
calculated given the incomplete nature of the data on HCS based on Malla et al. 
(2007). 
The base estimation assumes that 20 percent of the hydrogenated vegetable 
oils market are replaced by trans fat-free vegetable oils, leading to a 0.40g trans fat 
intake reduction daily in the UK. With the assumed 1:2 cholesterol to CHD risk ratio 
a saving of US$108 million in health-care costs is generated annually in the UK. 
The High level assumption is based on an optimistic perspective that trans 
fat-free vegetable oils cover a 50 percent market share in hydrogenated vegetable oils 
such as the shortening and the salad oil, accounting for a 0.99g trans fat intake 
reduction daily in the UK. With the assumption that every percentage change in total 
cholesterol leads to a 3 percent change in CHD and 1:1 ratio between the incidence of 
CHD and the resulting costs to society, the high level estimation results in a saving of 
US$405 million in the UK medical costs annually. 
For the Medium estimate, trans fat-free vegetable oil is assume to substitute 
for 40 percent of the hydrogenated vegetable oils market, which together results in a 
0.79g daily trans fat intake reduction individually in the UK. Given that a smaller 
ratio with every percentage change in cholesterol level which leads to a 2 percent 
reduction in CHD, this results in a saving of US$216 million in health-care costs 
annually in the UK based on an assumed 1:1 ratio between the incidence of CHD and 
the resulting costs to society. 87 
 
The low scenario demonstrates potential health-care cost savings under very 
conservative assumptions. Trans fat-free oils are assumed to reach only a 10 percent 
market share in the hydrogenated vegetable oils market. There is a 0.20g trans fat 
intake reduction daily in the UK. Further, a reduced ratio of 1:0.5 is applied between 
CHD change and health-care costs instead of the former 1:1 correlation. Although 
every step is extremely conservative, the extreme low scenario still suggests a 
potential reduction of US$27 million in health-care costs annually in the UK. 
Stage Three – Determine the Final Ratios for the UK Case Study 
 The  ratio η   which was discussed above is used to indicate the decision 
makers’ weighting of the changes in consumer surplus and producer surplus as well as 
the health cost savings arising from the imposition of an import ban on canola oil 
imports in the case of the United Kingdom. Table 12 shows the calculations 
undertaken to derive the ratios. From the table, the ratios for canola oil are calculated 
based on the results from the previous sections. In summary, in the absence of the 
information pertaining to the health benefits from canola oil η
M
  is equal to 1.19 in 
the base case, 1.05 in the high case, 1.11 in the medium case to 1.26 in the low case. 
With the health benefits, this ratio rises to 1.78 in the base case, 2.32 in the high case, 
2.0 in the medium case to 1.65 in the low case. 
The result shows that   
N
η is much larger than   
M
η at all four levels, which is 
consistent with the Chinese case study. Given the increased demand for canola oil in 
the UK market, consumers suffer a significant loss due to the higher domestic price 
caused by the import ban. Adding forgone health benefits and health care cost savings 88 
 
on canola oil into the ratio, the weighting ratio is considerably larger than before the 
health benefits of canola oil became known. In the High Case with 20 percent TFA 
reduction in daily trans fat intake, the loss for consumers arising from the 30 percent 
increased demand is more than two times larger than the gain by producers. At the 
low level, consumers still lose more than one and a half times the gain for producers. 
Therefore, from a welfare perspective, it is possible political decision makers may 
wish to re-consider their decisions on the import policy towards canola oil in the UK 




Table 12: Final Ratio Calculation in the U.K Case Study 
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Restrictions on market access for agricultural products have, for the most part, 
been in place for a long time – often many decades. Multilateral liberalization of 
market access for the sector has, historically, shown little progress. Currently, one of 
the major stumbling blocks to completion of the Doha Round of WTO negotiations is 
the question of market access for agricultural markets. The market for agricultural 
products, however, is not static with new products being introduced at a rapid pace. 
This changing marketplace for agricultural products calls into question whether trade 
restrictions put in place under entirely different market conditions remain appropriate. 
While broader questions pertaining to liberalization of market access are caught up in 
the politics of trade negotiations, countries always have the right to unilaterally 
remove barriers to market access. The question is, under what circumstances might 
they want to consider the unilateral option for selected markets? 
This paper has examined the question of revisiting the imposition of existing 
trade barriers in one case of an evolving marketplace – when a traditional food 
product is altered to provide, or discovered to have, human health benefits that 
increases their value to consumers. In other words, the food becomes a functional 
food. A functional food has the potential provide direct benefits to consumers as well 
as indirect benefits to society in the form of health care cost savings. If the trade 
barrier was put in place prior to these direct and indirect benefits of the food 
becoming apparent, then they would not have been considered when the decision to 91 
 
impose the trade barrier was taken. In these circumstances, policy makers may wish to 
revisit a decision to impose a trade barrier. 
As we could not find any previous research that considered this question, the 
objectives of this paper were to formally incorporate direct and indirect health 
benefits into a trade model and then to undertake two case studies to determine if the 
changes brought by functional foods are of a sufficient magnitude to justify further 
research in this area. Our theoretical work examined four cases: (1) A cost increasing 
trade barrier with domestic production of the functional food; (2) An import ban with 
domestic production of the functional food; (3) A cost increasing trade barrier without 
domestic production of the functional food and; (4) An import ban without domestic 
production of the functional food. The four cases produced effects that differed 
considerably suggesting that future examinations would have to be undertaken on a 
case by case basis. 
Barriers to market access for canola oil, which has been found to have 
additional health benefits associated with its consumption, were used for the empirical 
case studies. China imposes tariffs and produces canola domestically while market 
access to the United Kingdom is restricted by the European Union’s ban on imports of 
genetically modified organisms. Canola oil is, however, produced in the United 
Kingdom. The results suggest that, in both cases, a failure to consider health benefits 
in decisions pertaining to the imposition of trade barriers is a non-trivial matter. While, 
decision making pertaining to trade policy remains opaque, the results suggest that 
policy makers might wish to revisit decisions imposing trade barriers in the cases 92 
 
where functional foods are manifest in the marketplace. The results also suggest that 
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APPENDIX 1: CANOLA OIL 
SHIFTS IN DEMAND 
 
A1.1    Canola Oil Shift in Demand for China   
The trade model developed for functional food markets in this paper is based 
on two assumptions. First, the new product N, is assumed to be produced at the same 
cost as product M by both domestic and foreign suppliers. Second, product N can be 
represented by the same demand curve as product M and that the new health attribute 
does not change its price elasticity and, hence, there is no change in the slope of 
demand curve. From the perspective of consumers, more people are willing to buy the 
new health enhancing product N at the same price. Therefore, demand increases 
shifting out the demand curve. 
Based on these assumptions, in the Chinese case study, canola oil is assumed 
to benefit from an increase in demand and consumption due to the recent discovery of 
health giving attributes being associated with canola. Currently in China, however, 
there are no accurate surveys or reports on consumers’ attitudes to canola oil 
consumption after it became well-known for its trans fat-free attribute. Therefore, 
indirect evidence must be used to reveal the consumers’ behaviors towards trans 
fat-free canola oil. In other words, some way of determining the demand shift is 
needed to undertake calculations for the China case study. 
Healthcare Packaging (2007) suggests that functional food product markets 
are booming in the Asia Pacific because of the trend towards health and wellness. 
Consumer demands for convenience products and for healthier and functional 101 
 
products show an increasing trend (Taylor and Van Osdol, 2006; Bean, 2006). China's 
health food industry experienced rapid growth from the late 1980s to the late 1990s, 
with the fastest increase among the urban higher income population (Kotilainen et al., 
2006). China is leading the way in functional food market expansion in the Asia 
Pacific region. It is reported that the value of sales of functional foods grew by nearly 
20 percent in 2005 (Healthcare Packaging, 2007). Continued expansion of the 
functional foods market in China is predicted with a two-fold or larger growth in per 
capita spending on functional foods expected between 2004 and 2010 (Benkouider, 
2005). 
Thus, drawing on the reports and information outlined above, four levels of 
demand shift are assumed for the Chinese case study calculation. A base level is 
estimated with a 20 percent increase in demand for canola/rapeseed oil in the Chinese 
market. A two-fold expansion over the base case is set at 40 percent for the medium 
level and an even larger increase of 50 percent is assumed for the most optimistic case. 
Below the base level, a 10 percent shift in demand is assumed. 
A1.2 Canola Oil Shift in Demand for the UK 
In the UK case study, it is assumed that more people are willing to buy canola 
oil with newly recognized health enhancing attributes and consumers are willing to 
pay at least the same price or a premium for higher quality (health enhancing) canola 
oil. Therefore, the rising interest in new health enhancing canola oil shifts out the 
demand curve. However, with a GMO import ban, no imports of canola oil exist in 102 
 
the domestic market in the UK. Hence, domestic consumption rises to a new and 
higher autarky equilibrium. 
Canola (or rapeseed0 oil has been the most important vegetable oil produced 
in the European Union since 1988. In 10 years, EU consumption of vegetable oil has 
risen 50%, mainly due to increased consumption of rapeseed oil for its health 
attributes. Currently, rapeseed oil accounts for more than one-third of total European 
vegetable oil production and remains the largest oil consumed in Europe (MATIF, 
n.d.). 
At present, the competition between food consumption and biofuels usage is 
becoming a significant driver of the vegetable oils market and for rapeseed oil in 
particular. Currently, the production capacity for rapeseed is limited in the EU  — 
demand in rapeseed oil already exceeds supply. However, the GMO import ban on 
rapeseed/canola oil considerably restricts import sources from other countries and 
further raises the domestic price. 
A report from FEDIOL (2006) shows that the consumption of rapeseed oil in 
the UK market went up 48 percent from 0.43 million tones (Mt) to 0.63 Mt in the last 
15 years.   This increasing rate has slackened a bit in the last 5 years because of 
increases in the rapeseed oil price caused by the high competition for oil due to 
mandated bio-fuel usage. However, rapeseed oil remains the most widely consumed 
vegetable oil in the UK market, particularly since its health enhancing attributes 
became well known in the 1990s. 103 
 
Therefore, the UK case study is consistent with the two major assumptions of 
the model. First, the consumption of rapeseed oil is increasing due to the health giving 
attributes of rapeseed oil. Based on the information in FEDIOL (2006), four levels of 
increased demand are used in the UK’s case study calculations. A base level is 
estimated using a 30 percent increase in the domestic price for canola oil as a 
functional food in the UK market. A 40 percent change is used for the medium level. 
An even greater increase of 50 percent is assumed for the most optimistic case. Below 
the base level, a 15 percent demand increase is assumed for the most conservative 
case. 104 
 
APPENDIX 2: ESTIMATION AND CALCULATIONS   
FOR THE SAVINGS IN HEALTH COSTS 
 
Appendix 2 provides a more detailed estimation and calculation for some 
important data used in the case study.   
A2.1 Estimation of daily trans fat intake data in China 
While no studies on trans fat consumption in mainland China could be found, 
a study on trans fats in locally available foods conducted by the Centre for Food 
Safety (CFS) and the Consumer Council (CC) in Hong Kong, China is available. 
However, since results vary among different tested samples, no single estimate is 
available for the case study. Hence, an average estimate is required. Based on CFS 
(2007), the average trans fat daily intake for four major types of food were calculated. 
Combining the total trans fat consumption data from the CFS (2007)’s study, 
which used samples of 80 varied products, the final calculation of individual daily 
average trans fat intake is shown in table A2.1. Since the tested sample foods are not a 
major proportion of the Chinese diet, consumers may or may not choose all of the 
above four types of foods to include in their diet. Therefore, a 25 percent ratio is 
assigned to provide a conservative estimate. This ratio results in a total of 1.99g TFA 
























202.7 3.37  1.59  12.4  220.06 
Sample 
size(piece) 




6.14 0.13 0.11  1.55  7.94 
25% intake
 g 1.54  0.03  0.03  0.39  1.99 
a   Bread samples include sliced breads, buns, loaves, croissants and egg tarts. 
 
b Butter-made products includes cakes, waffles, egg puffs and egg rolls. 
c Fried products includes fries, fried chicken and oriental fried food. 
d margarine/margarine like spreads includes butter and margarine/margarine like spreads. 
 
e TFA is calculated from 100g/sample.   
 
f Average TFA(g) = Total TFA(g)/ Sample size(piece) 
g As the above sample foods are not frequently found in the common diet in China, it is assumed 
that there is only 25 percent chance that people will choose one of above four types foods in their 
daily diet. This means that 25 percent of total average TFA is the actual dietary intake assumed. 106 
 
A2.2 Assumed HCS rate (%)   
A2.2.1 Assumed HCS rate (%) in Chinese case study 
Recall the discussion on health care costs savings (HCS) suggested that they 
are likely to be some function of the consumption of the particular functional food. 
Therefore, the HCS that would arise from the removal of the trade barrier is a function 
of the increased consumption of product N. That is, 
 HCS  = ƒ( ΔQ
N ),  where  ΔQ
N is the difference between the consumption of N 
with a trade barrier and that which arises without the trade barrier. 
Following the analysis in Figure 7, the difference between the consumption of 
N with a trade barrier and that which arises without the trade barrier is measured by 
the quantity change along the demand curve D
N from Pw to (Pw + C). Thus, in the 
Chinese case study, the HCS would arise from the quantity change, which is a 
function of the increased consumption of trans fat-free canola oil along the new 
demand curve. 
Known as a functional food, trans fat-free canola oil is found to provide health 
enhancing benefits for consumers. However, prior to the scientific evidence 
discovered on its health enhancing attributes, canola oil has made health contributions 
to consumers since it was marketed. Therefore, all the people who consumed canola 
oil benefited from its health enhancing attributes and society received health savings 
due to reduced risk of CHD. Among the first three steps in section followed in the 
body of the paper, HCS calculations are based on consumption of canola oil in the 
entire domestic market, which is quantity Q
DN’. However, the health care costs 107 
 
savings (HCS) of interest is only those health improvement effect that can be 
attributed to trade liberalization. That means the HCS calculation should be focused 
on the quantity change of trans fat-free canola oil along the new demand curve. In 
order to limit the calculation to this group of individuals, a HCS rate is introduced into 
the last step calculation. The HCS rate is calculated as 
HCS rate = 
' DN
'   DN    DN
Q
Q   -   Q
    and is provided as a percent change  — details  can 
be found in the Table A2.2.   
By introducing the HCS rate in the Chinese case study, calculation for health 
care savings are concentrated on the expansion quantities in the market due to trade 
liberalization. Therefore, only those health care cost savings attributed to trade 














(40% demand shift) 
Base 
(20% demand shift) 
Low 
(10% demand shift) 
Q
DN(Mt)
 a 6.515  6.080  5.212  4.777 
Q
DN’ (Mt)
 b 6.409  5.981  5.127  4.699 
Q
DN - Q
DN’(Mt)  0.106 0.099  0.085  0.078 
HCS rate (%) =  '   DN
'   DN    DN
Q
Q   -   Q
  1.65% 1.66%  1.66%  1.66% 
a  Q
DN = Q
DM * (1+ demand shift rate)   
b Q
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=  where  D ε  is  -0.20,  (Pw + C) is 928.68 (US dollar/tonne) and (-C) is -76.68 (US dollar/tonne) from table 4.1 in section 4.3.2.1.109 
 
A2.2.2 Assumed HCS rate (%) in the UK case study 
A HCS rate is introduced into the last calculation step in the UK case study. The HCS 
rate is calculated as 
 
HCS rate =  EN
EN    DN
Q
Q   -   Q
  = 
0.63
0.63   -   0.77
  = 22 percent 
Where Q
DN is 0.77 Mt and
 Q
EN is 0.63 Mt from Table 8. 
By introducing the HCS rate in the UK case study, calculations for health care 
savings are concentrated on the expansion quantities in the market due to trade 
liberalization. Therefore, only those health care cost savings attributed to trade 
liberalization are included when determining the health care savings.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 